Gingrich Says "Boost NIH Biomed Research"

19 November 1997

The National Institutes of Health's budget for biomedical researchshould be doubled, according to US House Speaker Newt Gingrich, who added that the NIH should also be more aggressive in using information sciences to spread news about discoveries in medicine and science.

It should become more of an Internet and information age-oriented system, with total transparency so that people know what is being applied for, what is available and what kind of research is going on, he said. A constantly updated NIH Internet site should be developed, he said; these solutions will provide a way of empowering people with diseases to take some responsibility for their own care.

Also, doctors and health care providers should be informed about new breakthrough drugs and treatments no more than 12-18 months after they are discovered, he said, so that they are not practising medicine that is out-of-date.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight